NASDAQ$IONS
Ionis Pharmaceuticals · Q1 2020 earnings
Q1 2020 earnings · · Investor relations
Briefing
Ionis reported financial results for Q1 2020, highlighting commercial medicine performance and pipeline advancements.
Ionis Pharmaceuticals reported its Q1 2020 financial results, demonstrating strong performance in commercial medicines, particularly SPINRAZA, and advancements in its late-stage pipeline. The company reaffirmed its 2020 financial guidance, expecting to end the year meaningfully profitable, supported by commercial and R&D revenue. With a strong cash position of $2.4 billion, Ionis is well-capitalized to execute its strategic priorities.
- Commercial revenue growth driven by SPINRAZA royalties, which increased by more than 10% compared to Q1 2019.
- Product sales from TEGSEDI and WAYLIVRA more than doubled compared to Q1 2019.
- R&D revenue included over $25 million from Ionis’ neurology disease franchise and $15 million from its cardiometabolic franchise.
- The company reaffirmed its 2020 financial guidance, including ending 2020 meaningfully profitable.
Headline financials
Revenue & EPS history
Ionis · Revenue · Quarterly
$133M
Revenue by segment
Ionis · $151M total across 2 segments · Q2 2023
- Collaborative Agreement Rev$90M+130.8%59.6%
- SPINRAZA Royalties$61M+1.7%40.4%
Forward guidance
Ionis reaffirmed its 2020 financial guidance, including ending 2020 meaningfully profitable. The company expects results to be driven by continued commercial and R&D revenue.
Tailwinds
- Initiate the Phase 3 study of AKCEA-APOCIII-LRx in patients with FCS
- Refile WAYLIVRA new drug application for U.S. marketing authorization
- File for WAYLIVRA marketing approval in Brazil with PTC Therapeutics
- Report clinical proof-of-concept results for four or more programs
- Advance five or more new medicines into development, including several Ionis-owned medicines
Headwinds
- Forward-looking statements are subject to risks and uncertainties, including those related to the impact COVID-19 could have on our business
- Risks related to commercial products and medicines in the pipeline
- Risks inherent in the process of discovering, developing and commercializing medicines that are safe and effective for use as human therapeutics
- Ionis' forward-looking statements also involve assumptions that, if they never materialize or prove correct, could cause its results to differ materially
- You are cautioned not to rely on these forward-looking statements
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q1 2020
+0.2%
Avg return
Earnings day
+1.9%
Avg return
5 days after
+1.2%
Avg return
30 days after
51%
35 / 68 earnings
Positive
+30.2%
Q3 2016
Best reaction
-13.5%
Q3 2011
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +4.2% | +5.1% | +6.6% | |
| Q4 2025 | -5.3% | -4.1% | -15.6% | |
| Q3 2025 | -2.3% | +0.1% | +12.5% | |
| Q1 2025 | +3.0% | +12.9% | +12.4% | |
| Q4 2024 | -0.4% | -0.2% | +3.0% | |
| Q3 2024 | -0.9% | +0.2% | -1.8% | |
| Q2 2024 | -0.7% | -4.9% | -3.6% | |
| Q1 2024 | -5.0% | -7.6% | -5.7% | |
| Q4 2023 | -0.8% | +3.9% | -3.7% | |
| Q3 2023 | +4.3% | +5.4% | +14.1% | |
| Q2 2023 | +0.7% | +0.8% | +4.2% | |
| Q1 2023 | +1.3% | -1.0% | +17.5% | |
| Q4 2022 | -4.0% | -5.3% | -11.2% | |
| Q3 2022 | +7.6% | +4.2% | -11.2% | |
| Q2 2022 | +0.9% | -3.5% | -3.2% | |
| Q1 2022 | -1.2% | -17.6% | -6.1% | |
| Q4 2021 | +3.4% | +10.9% | +19.3% | |
| Q3 2021 | +5.0% | +5.8% | -20.0% | |
| Q2 2021 | +4.2% | +2.0% | +4.5% | |
| Q1 2021 | -11.1% | -13.7% | -17.7% | |
| Q4 2020 | -4.7% | -3.6% | -23.4% | |
| Q3 2020 | +3.7% | +6.6% | +9.0% | |
| Q2 2020 | -4.6% | -8.7% | -6.1% | |
| Q1 2020 | -7.7% | -2.7% | -0.3% | |
| Q4 2019 | -3.6% | -5.4% | -10.7% | |
| Q3 2019 | +1.8% | +4.2% | +18.8% | |
| Q2 2019 | +6.6% | +6.2% | -3.6% | |
| Q1 2019 | +0.9% | -2.8% | -7.2% | |
| Q4 2018 | +15.2% | +14.4% | +31.7% | |
| Q3 2018 | +5.4% | -0.0% | +8.8% | |
| Q2 2018 | +4.4% | +11.6% | +1.9% | |
| Q1 2018 | +7.4% | +3.7% | +12.9% | |
| Q4 2017 | +2.8% | -4.7% | -14.2% | |
| Q3 2017 | +0.9% | +3.0% | -0.6% | |
| Q2 2017 | -8.6% | -11.0% | +7.4% | |
| Q1 2017 | -2.6% | +3.9% | +10.3% | |
| Q4 2016 | +5.4% | +16.6% | -13.8% | |
| Q3 2016 | +30.2% | +51.0% | +44.9% | |
| Q2 2016 | +0.1% | -2.5% | -14.1% | |
| Q1 2016 | -8.7% | — | — | |
| Q4 2015 | -4.6% | — | — | |
| Q3 2015 | +14.8% | — | — | |
| Q2 2015 | +1.0% | — | — | |
| Q1 2015 | +1.2% | — | — | |
| Q4 2014 | -0.8% | — | — | |
| Q3 2014 | +4.4% | — | — | |
| Q2 2014 | +6.3% | — | — | |
| Q1 2014 | -6.5% | — | — | |
| Q4 2013 | -9.7% | — | — | |
| Q3 2013 | -6.1% | — | — | |
| Q2 2013 | -4.2% | — | — | |
| Q1 2013 | -12.4% | — | — | |
| Q4 2012 | +7.6% | — | — | |
| Q3 2012 | -7.0% | — | — | |
| Q2 2012 | +3.9% | — | — | |
| Q1 2012 | +7.6% | — | — | |
| Q4 2011 | +2.8% | — | — | |
| Q3 2011 | -13.5% | — | — | |
| Q2 2011 | -8.2% | — | — | |
| Q1 2010 | -2.7% | — | — | |
| Q1 2011 | +2.8% | — | — | |
| Q4 2008 | -1.6% | — | — | |
| Q4 2010 | -1.6% | — | — | |
| Q3 2009 | +2.5% | — | — | |
| Q3 2010 | +2.5% | — | — | |
| Q4 2009 | -3.8% | — | — | |
| Q2 2010 | -3.8% | — | — | |
| Q2 2009 | -3.8% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro